GDC-0199

venetoclax · AbbVie (co-developed with Genentech/Roche)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GDC-0199, covering 2026-01-27 to 2026-01-27. Get the full timeline:

Most recent: Clinical Trial Update: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

See pricing